Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON
  1. Homepagina
  2. Aandelen
  3. Frankrijk
  4. Euronext Paris
  5. Sanofi
  6. Nieuws
  7. Persberichten
    SAN   FR0000120578

SANOFI

(SAN)
Real-time koersen. Real Time Euronext Paris - 27/09 17:36:18
82.12 EUR   +0.12%
08:27Sanofi's mRNA COVID-19 Jab-kandidaat vertoont positieve resultaten in Fase 1/2 studie
MT
27/09SANOFI : SVB Leerink verhoogt advies
MM
23/09SANOFI : Deutsche Bank is negatief
MD
OverzichtKoersenGrafiekenNieuwsRatingenAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuwsAnalyse MarketScreener
Communiquťs de presse de la sociťtť SANOFI
08:01Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vacc..
GL
27/09SANOFI : - Availability of the Q3 2021 Memorandum for modelling purposes
AQ
27/09SANOFI : New research presented at IDWeek 2021 reinforces Sanofi's robust vaccines pipelin..
PU
24/09SANOFI : Availability of the Q3 2021 Memorandum for modelling purposes
AQ
23/09SANOFI : New Dupixentģ (dupilumab) data in patients as young as 6 years old with moderate-..
PU
21/09SANOFI : New Dupixentģ (dupilumab) data in patients as young as 6 years old with moderate-..
AQ
20/09SANOFI : - ESMO late-breaking data show Libtayo (cemiplimab) and chemotherapy first-line t..
AQ
19/09SANOFI : ESMO late-breaking data show Libtayoģ (cemiplimab) and chemotherapy first-line tr..
AQ
15/09TRANSLATE BIO : LifeSci Index Partners
AQ
14/09SANOFI : completes acquisition of Translate Bio, accelerating the application of mRNA in n..
PU
14/09SANOFI : completes acquisition of Translate Bio, accelerating the application of mRNA in n..
AQ
10/09SANOFI : provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pe..
PU
09/09SANOFI : provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pe..
GL
08/09SANOFI : to acquire Kadmon to further strengthen growth of transplant business (Form 6-K)
PU
08/09SANOFI : to acquire Kadmon to further strengthen growth of transplant business
AQ
03/09SANOFI : Dupixentģ (dupilumab) efficacy and quality of life data in asthma patients across..
PU
01/09ACURX PHARMACEUTICAL'S IS DISRUPTIVE : Acxp)
AQ
30/08SANOFI : Dupixentģ (dupilumab) pivotal trial meets all primary and secondary endpoints bec..
GL
26/08Acurx Pharmaceuticals Plan To Change The Antibiotics Landscape Is Simple- Make Better D..
AQ
17/08Acurx Pharmaceutical's On Pace To Change The Antibiotics Landscape; Trial Data Shows 10..
AQ
12/08SANOFI : Corrective to Aug. 10 story on Moderna building a production plant in Canada
AQ
12/08DRUG MAKERS OVERSEAS ARE GAINING A C : Acxp)
AQ
09/08GRAM POSITIVE BACTERIAL INFECTIONS C : Acxp)
AQ
06/08SANOFI : FDA approves Nexviazymeģ (avalglucosidase alfa-ngpt), an important new treatment ..
GL
06/08SANOFI : - Phase 3 trial of Libtayo combined with chemotherapy stopped early due to signif..
AQ
06/08SANOFI : Bionity - Sanofi to acquire Translate Bio
AQ
06/08TRANSLATE BIO : Announces Second Quarter 2021 Financial Results and Provides Corporate Upd..
AQ
05/08SANOFI : Phase 3 trial of Libtayoģ (cemiplimab) combined with chemotherapy stopped early d..
GL
04/08SANOFI : to acquire Translate Bio, advances deployment of mRNA technology across vaccines ..
AQ
04/08SANOFI : to acquire Translate Bio; advances deployment of mRNA technology across vaccines ..
PU
03/08SANOFI : Online availability of Sanofi's half-year financial report for 2021 (Form 6-K)
PU
03/08SANOFI : to acquire Translate Bio; advances deployment of mRNA technology across vaccines ..
GL
30/07REGENERON PHARMACEUTICALS : Dupixent significantly improved itch and hives in patients wit..
AQ
30/07AMGEN : Federal Circuit Emphasizes High Bar For Enablement Of Functional Claims
AQ
29/07SANOFI : Online availability of Sanofi's half-year financial report for 2021
GL
29/07SANOFI : Sales growth accelerated - Full-year guidance raised (Form 6-K)
PU
29/07SANOFI : Q2 Earnings Snapshot
AQ
29/07SANOFI : appoints new leaders to Executive Committee and announces future Chair of EUROAPI
GL
29/07SANOFI : Sales growth accelerated - Full-year guidance raised
GL
29/07SANOFI : Dupixentģ (dupilumab) significantly improved itch and hives in patients with chro..
GL
27/07SANOFI : provides update on avalglucosidase alfa EU submission for patients with Pompe Dis..
PU
22/07SANOFI : continues streamlining of established products with sale of dental care brands to..
PU
20/07SANOFI : - US FDA approves fexinidazole as the first all-oral treatment for sleeping sickn..
AQ
19/07SANOFI : US FDA approves fexinidazole as the first all-oral treatment for sleeping sicknes..
PU
16/07SANOFI : announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in ..
PU
15/07SANOFI : Conversion of Kiadis to a private limited liability company postponed until compl..
PU
13/07SANOFI : streamlines Consumer Healthcare portfolio in Latin America with divestiture of ei..
PU
13/07SANOFI : announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in ..
AQ
12/07SANOFI : - MenQuadfi demonstrates superior immune response against serogroup C meningococc..
AQ
10/07SANOFI : MenQuadfiģ demonstrates superior immune response against serogroup C meningococca..
PU
07/07SWEDISH ORPHAN BIOVITRUM : Sobi to present data at the ISTH 2021 within rare haematology d..
AQ
02/07SANOFI : highlights scientific innovations in the field of rare blood disorders at ISTH 20..
PU
30/06SANOFI : Approximately Ä400million investment annually to accelerate end-to-end R&D of nex..
PU
29/06SANOFI : launches dedicated vaccines mRNA Center of Excellence
AQ
28/06SANOFI : - Availability of the Q2 2021 Memorandum for modelling purposes
AQ
28/06SANOFI : - Libtayo approved by the European Commission as the first immunotherapy indicate..
AQ
28/06SANOFI : New Soliquaģ data shows improved blood sugar control without weight gain versus p..
PU
28/06SANOFI : Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial
GL
28/06SANOFI : streamlines Consumer Healthcare portfolio in Europe with divestiture of 16 brands..
PU
28/06Dupixentģ (dupilumab) SmPC updated with long-term data reinforcing well-established saf..
GL
25/06SANOFI : European Commission approves Aubagioģ (teriflunomide) as the first oral MS therap..
PU
25/06SANOFI : Availability of the Q2 2021 Memorandum for modelling purposes
AQ
25/06SANOFI : Libtayoģ (cemiplimab) approved by the European Commission as the first immunother..
GL
25/06SANOFI : Libtayoģ (cemiplimab) approved by the European Commission for first-line treatmen..
GL
18/06SANOFI : European Commission approves Aubagioģ (teriflunomide) as the first oral MS therap..
AQ
16/06ER+/ HER2-VE BREAST CANCER PIPELINE : Emerging Therapies and Key pharma players involved b..
AQ
14/06SANOFI : - New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investig..
AQ
14/06SANOFI : provides update on Aubagio (teriflunomide) submission for children and adolescent..
AQ
11/06New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational ..
GL
11/06SANOFI : provides update on Aubagioģ (teriflunomide) submission for children and adolescen..
PU
08/06SANOFI : launches its new global employee share ownership plan (Form 6-K)
PU
07/06SANOFI : launches its new global employee share ownership plan
GL
07/06Compatibility with New Insulins Opens Up New Market Opportunities for Brighter's Actist..
AQ
07/06SANOFI : partnering with leading academic cooperative groups to study amcenestrant in the ..
AQ
04/06Sanofi partnering with leading academic cooperative groups to study amcenestrant in the..
GL
1  2  3  4  5  6  7  8  9  10Volgende
Volgende evenement op SANOFI
30/09/21